Supplemental Figure 6

Oct 04, 2014

10 likes | 99 Views

Supplemental Figure 6.

Share Presentation

Embed Code

Link

supplemental figure 6

paco

Download Presentation

Supplemental Figure 6

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 6

Supplemental Figure 1

Supplemental Figure 1. Fig. S1 qRT -PCR analysis of the genes flanking the sbp2’ / sbp2’’ knockouts. All values are given relative to the abundance of transcript observed in P1/7. Data presents the mean from 3 biological replicates. .

101 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Purified Collagens. A). B). Purified Collagen1 ( μ g). 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Purified Col1. Purified Col3. Col1. Purified Collagen3 ( μ g). Col1. 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Col3. Col3. Col1. Col3. Arbitrary Units.

122 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. d-ROM (Carr U). P = 0.0512. recurrence-free period (day). Correlation between d-ROM levels and recurrence-free period in 36 multicentric occurrence cases using linear regression analysis.

80 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

76 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Time course of mean arterial pressure, albuminuria, and kidney injury after reduction in renal mass and treatment of C57BL/6 mice with deoxycorticosterone acetate + saline drinking water (DOCA) or treatment of CD-1 mice with hydralazine.

135 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. P-VEGFR2. Tubulin. PlGF-1 250 ng/mL - + + + + Time (min) - 5 10 15 30. B. P-VEGFR2. Tubulin. C.

95 views • 3 slides

Supplemental Figure 5

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

119 views • 1 slides

Supplemental Figure 2

MK-1775. MK-1775 + 37.5 nM MK-8776. MK-1775 + 75 nM MK-8776. MK-1775 + 150 nM MK-8776. MK-1775 + 300 nM MK-8776. Supplemental Figure 2. A. B. HRE cells. fractional proliferation. MK-8776 ( μ M). MK-1775 ( μ M).

112 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. SPERM A -. Sp_D62[A-]. Sp_D62[A+]. SPERM A +. Sp_D62[Tt]. SPERM TOTAL. Sp_D64[Tt]. Sp_D66[Tt]. Sp_P1[Tt]. Sp_D62[SP]. SPERM SPIA. Sp_D64[SP]. Sp_D66[SP]. Sp_P2[SP]. Te_PCl[SP]. TESTES SPIA. Te_PAm[A+]. TESTES Poly (A + ). Te_PCl[A+]. PRM2.

181 views • 6 slides

Supplemental Figure S1

Supplemental Figure S1. A. MDA-MB-231 BCL-2. MCF-7 BCL-2. MDA-MB-231. MCF-7. Bcl-2. Bcl-2. Actin. Actin. B. Supplemental Figure S2. **. *. *. *. *. Control. - - - - - - -. Cisplatin 30 M.

126 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. Supplemental Figure 2. Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF on HCC827 cell.

166 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. a. Relative expression. b. Relative expression. c. Relative expression.

104 views • 1 slides

Supplemental Figure 3

99 views • 2 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

134 views • 1 slides

Supplemental Figure 2

si RNA #1. si RNA #1. si RNA #1. si RNA #1. si RNA #2. si RNA #2. si RNA #2. si RNA #2. si RNA #3. si RNA #3. si RNA #3. si RNA #3. si control. si control. si control. si control. Casp-9. Casp-2. 47kDa. 51kDa. b -actin. b -actin. Relative mRNA expression. RAIDD. PIDD.

129 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. True leaf from 2 nd to 7 th nodes. (a). M. 1 st (IN) IN. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. PC. ALSV-RNA2. 7. PsEF1- a. 6. 1. 2. 3. 5. True leaf from 2 nd to 7 th nodes. ALSV inoculation. 4. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. 3. Mock. 2.

98 views • 3 slides

Supplemental Figure.

Supplemental Figure. Legend:

91 views • 3 slides

Supplemental Figure 6

*. *. A. B. phospho-AMPK. **. 4. AMPK. 3. vehicle. g-Adipo. Phospho / total (fold). phospho-mTOR. 2. 1. mTOR. 0. AMPK. phospho-p70 S6K. 1.2. 1.0. P70 S6K. 0.8. Phospho / total (fold). 0.6. **. 0.4. phospho-S6 protein. 0.2. 0. S6 protein. mTOR. p70 S6K. S6 protein.

121 views • 1 slides

Glazov et al., Supplemental Figure 6

Glazov et al., Supplemental Figure 6.

131 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3.

76 views • 1 slides

Figure I supplemental

Figure I supplemental.

172 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. a. ADP titration (Clark-type electrode). ~10.00. ~10.27. ~7.01. ~5.11. ~5.00. ~4.03. ADP titration (Seahorse XF24). b. ~3.89. ~3.10. ~2.62. ~2.03. ~1.63. c. Mitochondrial integrity test (Clark-type electrode). d.

116 views • 2 slides

More Related